The only reported case of CRISPR employment against TGFβ pathway for cancer-related purposes dates to 2020 and was used to knock-out TGF-BRII receptor in Chimeric Antigen Receptor T cells (CAR-T cells), making them insensitive to microenvironment TGFβ and allowing for a longer-lasting solid tumor-cytotoxic response [36]. The gene discussed is TGFB1; the disease is cancer.